Navigation Links
Novel target found for chemotherapy-resistant leukemia cells
Date:5/12/2014

Researchers at Children's Hospital Los Angeles have discovered that by targeting a particular receptor, chemotherapy-resistant cancer cells can be killed in an acute form of childhood leukemia, offering the potential for a future treatment for patients who would otherwise experience relapse of their disease.

Nora Heisterkamp, PhD, and colleagues at The Saban Research Institute of Children's Hospital Los Angeles have discovered that by targeting the B-cell activating receptor (BAFF-R), chemotherapy-resistant precursor B acute lymphoblastic leukemia cells (pre-B ALL) can be selectively killed in vivo and in vitro. Results will be published on May 13 in Molecular Cancer Therapeutics.

Acute lymphoblastic leukemia (ALL) is characterized by an excessive amount of white blood cell precursors, called B-cell lymphoblasts, in the blood and bone marrow. B-cell lineage ALL (pre-B ALL) accounts for 80 to 85% of childhood ALL. Although the cure rate has increased, further advances can only be achieved by identifying mechanisms to treat specific subsets of chemotherapy-resistant leukemia cells.

In a previous study (Leukemia, 2013), the researchers had shown that BAFF-R is expressed on pre-B ALL cells but not on their normal counterparts, making selective killing of ALL cells possible by targeting this receptor.

"We've now demonstrated that BAFF-R is a strong potential therapeutic target for treating chemotherapy-resistant leukemia cells, without damaging healthy cells," said Heisterkamp, who is also professor of Research, Pediatrics and Pathology at the Keck School of Medicine of the University of Southern California.

Using a genetically-engineered antibody (anti-BAFF-R monoclonal antibody), Heisterkamp and colleagues have demonstrated that the BAFF-R could be successfully blocked in a dose-dependent manner. Inhibition of BAFF-R function rendered leukemia cells less viable in mouse models of the disease. Also, the presence of this antibody on the pre-B ALL cells resulted in increased killing of the cancer cells by natural killer (NK) cells and macrophages.

"We found that human pre-B ALL cells could be even further reduced when the anti-BAFF-R antibody was combined with chemotherapy or another therapeutic agent," said Heisterkamp. "We are looking at a potential one, two punch." Heisterkamp and her colleagues will continue to evaluate the use of this antibody for the treatment of ALL.


'/>"/>

Contact: Ellin Kavanagh
ekavanagh@chla.usc.edu
323-361-8505
Children's Hospital Los Angeles
Source:Eurekalert  

Related medicine news :

1. Novel compound demonstrates anti-leukemic effect in zebrafish, shows promise for human treatment
2. Rutgers team discovers novel approach to stimulate immune cells
3. Novel drug candidates offer new route to controlling inflammation
4. Researchers present new findings for novel pancreatic cancer vaccine
5. Novel biomarkers reveal evidence of radiation exposure
6. VCU Massey Cancer Center sees potential in novel leukemia treatment
7. Study supports urate protection against Parkinsons disease, hints at novel mechanism
8. Novel Natural Sciences Repository Opens Web Portal
9. Novel Anti-Inflammatories May Offer a New Approach for the Treatment of Stroke
10. LA BioMed investigators, Drs. Kevin Bruhn and Noah Craft, develop novel treatment for melanoma
11. Novel radiation therapy safely treats prostate cancer and lowers the risk of recurrence
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Novel target found for chemotherapy-resistant leukemia cells
(Date:1/17/2017)... CO (PRWEB) , ... January 17, 2017 , ... ... protection and financial planning assistance to families and business professionals throughout central Colorado, ... to regional homeless families. , The Aurora Warms The Night organization is committed ...
(Date:1/17/2017)... ... January 17, 2017 , ... Physicians Education Review®, LCC ... keynote speaker for the 34th Annual Miami Breast Cancer Conference®, on March 9-12, ... president, Phil Talamo, said, “We are delighted to have Sandra Lee join us ...
(Date:1/17/2017)... TX (PRWEB) , ... January 17, 2017 , ... Today, ... USA Wrestling announced a new agreement as part of a long-term extension ... December 2024 and includes the airing of some of the sport’s premier events exclusively ...
(Date:1/16/2017)... ... January 16, 2017 , ... California Southern University has named Dr. ... CalSouthern’s Board of Trustees and as a core faculty member, teaching master’s and doctoral ... professor of psychology at Pepperdine University, where he earned his Doctor of Psychology degree ...
(Date:1/16/2017)... ... January 16, 2017 , ... Anybody who may be looking for a substance ... released by Serenity Recovery, a holistic treatment center for addiction located in Marne, MI. ... and testimonials from patients and staff that visited the 2016 Recovery Palooza support event ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... Jan. 17, 2017 EU5 Glucose Monitoring Market ... report, "EU5 Glucose Monitoring Market Outlook to 2022", provides ... The report provides value, in millions of US dollars, ... segments - Blood Glucose Meters, Blood Glucose Test Strips ... and distribution shares data for each of these market ...
(Date:1/17/2017)... Jan. 17, 2017 Paragon Bioservices received a ... development services for a variety of National ... medical product development activities. The IDIQ mechanism will ... for task order awards up to $159 million. ... manufacturing and process development of biopharmaceuticals, is one ...
(Date:1/17/2017)... 2017  Pennsylvania Secretary of Health Dr. ... marijuana growers/processors and dispensaries are now available on ... Permit applications will be accepted from February 20 ... an important step forward in getting this valuable ... Murphy said. "We,ve developed a thorough application that ...
Breaking Medicine Technology: